Adam Bonislawski

Since the proteomics facility launched in 2019, revenues have roughly doubled each year and it has doubled its staff, with biopharma driving much of the demand.

The company plans to use Planegg, Germany-based OmicEra’s mass spectrometry-based proteomics technologies for cancer biomarker discovery.

CEO Michael Egholm, a former Danaher exec, said he sees Standard BioTools’ flaws as emblematic of problems hampering the broader life science tools industry.

While deals got done, it was a far cry from the boom times of 2021, with firms becoming more circumspect as they anticipated a possible recession and falling valuations.

Such direct infusion mass spec workflows are niche within proteomics, but sample handling and ion mobility advances could drive future adoption.

The method combines tissue clearing and high-sensitivity mass spec to enable identification and proteomic profiling of affected cells early in a disease process.

Its developers have founded a company, Atavistik Bio, to commercialize the method, which has applications in drug development and basic research.

Highlights from the first day included Exact Sciences' growth expectations for Cologuard, Qiagen's FDA clearance of a NeuMoDx test, and NeoGenomics' plans to push ahead with its MRD test despite an injunction.

Applications like de novo protein sequencing and posttranslational modification analysis are receiving a boost from AI, though implementation can be challenging.